Dantrolene Sodium


|Dantrolene Sodium

Drugs search, click the first letter of a drug name:

| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Dantrolene Sodium

Pronouncation: (dan-troe-LEEN SO-dee-uhm)
Class: Skeletal muscle relaxant

Trade Names:
- Capsules 25 mg
- Capsules 50 mg
- Capsules 100 mg

Trade Names:
Dantrium Intravenous
- Powder for Injection 20 mg/vial (approximately 0.32 mg/mL after reconstitution)

Mechanism of Action


Affects contraction of muscle at site beyond myoneural junction and directly on muscle itself; believed to interfere with calcium release from sarcoplasmic reticulum. Affects CNS, causing drowsiness, dizziness, and generalized weakness.




Absorption is incomplete and slow, but consistent.


Significantly protein bound, mostly albumin.


Metabolized in the liver to the major metabolites 5-hydroxy dantrole and an acetylamino metabolite.


t ½ is 4 to 8 hr (IV), 9 hr (oral).

Indications and Usage

Control of spasticity associated with spinal cord injury, stroke, cerebral palsy or multiple sclerosis; prophylaxis, treatment and postcrisis therapy of malignant hyperthermia.

Unlabeled Uses

Management of exercise-induced muscle pain, neuroleptic malignant syndrome, heat stroke.


Active hepatic disease; muscle spasm resulting from rheumatic disorders; where spasticity is used to sustain upright posture and balance in locomotion or to obtain or maintain increased function.

Dosage and Administration

Chronic Spasticity

PO Initial dose 25 mg q day; increase at 4 to 7 day intervals to 25 mg bid to qid, up to max 100 mg bid to qid if necessary.


PO Initial dose 0.5 mg/kg bid; increase to 0.5 mg/kg tid to qid, then by increments of 0.5 mg/kg, up to 3 mg/kg bid to qid, if necessary. Max 100 mg qid.

Malignant Hyperthermia
Adults and Children Preoperative prophylaxis

PO 4 to 8 mg/kg/day in 3 or 4 divided doses for 1 or 2 days prior to surgery with last dose given 3 to 4 hr before surgery or IV 2.5 mg/kg approximately 75 min before anesthesia. Infused over 1 hr. May repeat during surgery, if needed.


IV 1 mg/kg by continuous rapid push; evaluate and repeat as needed until cumulative total dose is up to 10 mg/kg.

Postcrisis follow-up

PO 4 to 8 mg/kg/day in 4 divided doses for 1 to 3 days to prevent recurrence. If IV route must be utilized, start with at least 1 mg/kg, as needed.

General Advice

  • Ensure good IV site using large peripheral vein; medication is very irritating to tissues.
  • Reconstitute powder for IV infusion in 60 mL of sterile water without bacteriostatic agent.
  • Shake until solution is clear.


Store at room temperature for up to 6 hr. Protect from direct light.

Drug Interactions


Plasma protein binding of dantrolene reduced.


Women receiving these may be at increased risk for hepatotoxicity.


Hyperkalemia and myocardial depression possible.


Plasma protein binding of dantrolene reduced.

Laboratory Test Interactions

None well documented.

Adverse Reactions

Caused by oral administration except where otherwise indicated.


Tachycardia; erratic BP; phlebitis.


Drowsiness; dizziness; weakness; general malaise; fatigue; speech disturbances; seizures; headache; lightheadedness; insomnia, mental depression or confusion; increased nervousness.


Abnormal hair growth; acne-like rash; pruritus; urticaria (IV); eczematoid eruption; sweating; erythema (IV).


Visual disturbance, diplopia, alteration of taste.


Diarrhea; constipation; bleeding; anorexia; dysphagia; gastric irritation; abdominal cramps.


Increased urinary frequency; hematuria; crystalluria; difficult erection; urinary incontinence; nocturia; dysuria; urinary retention.




Pleural effusion with pericarditis; pulmonary edema (IV).


Myalgia; backache; chills; fever; feeling of suffocation; excessive tearing; thrombophlebitis (IV).



Should not be used in conditions other than those recommended.


The incidence of symptomatic (fatal and nonfatal) hepatitis is lower with doses up to 400 mg/day compared with 800 mg/day or greater. Overt hepatitis was most frequent during the third and twelfth mo but may occur at anytime. Risk is higher in females, patients older than 35 yr, and with concurrent therapy. Use only in conjunction with liver monitoring.


Category C (parenteral).


Do not use in nursing women.


Safety in children younger than 5 yr not established.

Hepatic Function

Fatal and nonfatal liver disorders may occur; use drug with caution in patients with pre-existing hepatic impairment and in women and patients older than 35 yr.

Special Risk Patients

Use drug with caution in patients with impaired pulmonary function (especially COPD) or cardiac function.


Photosensitization may occur.


Because of the high pH of the IV formulation, prevent extravasation into the surrounding tissue.

IV Dantrolene

IV dantrolene is also associated with the loss of grip strength and weakness in the legs.

Long-term use

Safety and efficacy not established; use only if significant pain or disability is present or nursing care is reduced. Consider carcinogenicity risk and liver damage with long-term use. Discontinue therapy if no benefit within 45 days.

Malignant hyperthermia

Supportive care should be foremost in treatment (ie, concurrent with dantrolene therapy).

Patient Information

  • Teach patient and family the name, action, administration, and side effects of dantrolene.
  • Emphasize importance of follow-up exams and laboratory work to monitor drug therapy.
  • Instruct patient to report these symptoms to health care provider: weakness, malaise, fatigue, nausea, diarrhea, skin rash, itching, bloody or black tarry stools, yellowish discoloration of skin.
  • Instruct patient to avoid intake of alcoholic beverages or other CNS depressants.
  • Advise patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness.
  • Caution patient to avoid exposure to sunlight and to use sunscreen or wear protective clothing to avoid photosensitivity reaction.
  • Caution patient that dantrolene may decrease grip strength and increase weakness of leg muscles especially when walking down stairs.
  • Advise patients to exercise caution in eating on day of administration because difficulty swallowing and choking is possible.

Where can I get more information about Dantrolene Sodium ? We recommend to use www.Drugs.com

Typical mistypes for Dantrolene Sodium
santrolene sodium, xantrolene sodium, cantrolene sodium, fantrolene sodium, rantrolene sodium, eantrolene sodium, dzntrolene sodium, dsntrolene sodium, dwntrolene sodium, dqntrolene sodium, dabtrolene sodium, damtrolene sodium, dajtrolene sodium, dahtrolene sodium, danrrolene sodium, danfrolene sodium, dangrolene sodium, danyrolene sodium, dan6rolene sodium, dan5rolene sodium, danteolene sodium, dantdolene sodium, dantfolene sodium, danttolene sodium, dant5olene sodium, dant4olene sodium, dantrilene sodium, dantrklene sodium, dantrllene sodium, dantrplene sodium, dantr0lene sodium, dantr9lene sodium, dantrokene sodium, dantropene sodium, dantrooene sodium, dantrolwne sodium, dantrolsne sodium, dantroldne sodium, dantrolrne sodium, dantrol4ne sodium, dantrol3ne sodium, dantrolebe sodium, dantroleme sodium, dantroleje sodium, dantrolehe sodium, dantrolenw sodium, dantrolens sodium, dantrolend sodium, dantrolenr sodium, dantrolen4 sodium, dantrolen3 sodium, dantrolene aodium, dantrolene zodium, dantrolene xodium, dantrolene dodium, dantrolene eodium, dantrolene wodium, dantrolene sidium, dantrolene skdium, dantrolene sldium, dantrolene spdium, dantrolene s0dium, dantrolene s9dium, dantrolene sosium, dantrolene soxium, dantrolene socium, dantrolene sofium, dantrolene sorium, dantrolene soeium, dantrolene soduum, dantrolene sodjum, dantrolene sodkum, dantrolene sodoum, dantrolene sod9um, dantrolene sod8um, dantrolene sodiym, dantrolene sodihm, dantrolene sodijm, dantrolene sodiim, dantrolene sodi8m, dantrolene sodi7m, dantrolene sodiun, dantrolene sodiuk, dantrolene sodiuj, antrolene sodium, dntrolene sodium, datrolene sodium, danrolene sodium, dantolene sodium, dantrlene sodium, dantroene sodium, dantrolne sodium, dantrolee sodium, dantrolen sodium, dantrolenesodium, dantrolene odium, dantrolene sdium, dantrolene soium, dantrolene sodum, dantrolene sodim, dantrolene sodiu, adntrolene sodium, dnatrolene sodium, datnrolene sodium, danrtolene sodium, dantorlene sodium, dantrloene sodium, dantroelne sodium, dantrolnee sodium, dantroleen sodium, dantrolen esodium, dantrolenes odium, dantrolene osdium, dantrolene sdoium, dantrolene soidum, dantrolene soduim, dantrolene sodimu, ddantrolene sodium, daantrolene sodium, danntrolene sodium, danttrolene sodium, dantrrolene sodium, dantroolene sodium, dantrollene sodium, dantroleene sodium, dantrolenne sodium, dantrolenee sodium, dantrolene sodium, dantrolene ssodium, dantrolene soodium, dantrolene soddium, dantrolene sodiium, dantrolene sodiuum, dantrolene sodiumm, etc.

© Copyright by drug-information.ru 2001-2019. All rights reserved